• Home
  • Industry News
  • Lilly announces top-line results of solanezumab phase 3 clinical trial

Lilly announces top-line results of solanezumab phase 3 clinical trial


Eli Lilly and CompanyEli Lilly and Company (NYSE: LLY) today announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).

Source link